Medical Pharmacology Question Bank
Chapter 8: Antiarrhythmic Drugs — Module 3: Class II Beta-Blockers in Arrhythmia Management
Core Concepts — Foundational Knowledge (22 questions)
BEFORE YOU BEGIN
This set covers the pharmacology of Class II antiarrhythmic agents — the beta-blockers. These drugs are among the most widely prescribed in cardiovascular medicine, and understanding why they work requires connecting receptor biology to cardiac electrophysiology. Some questions here are straightforward recognition and classification; others ask you to connect mechanism to clinical effect. Work through all of them, and read every rationale — including the ones you get right. The rationale is where the learning happens.
1. Beta-adrenergic receptors in cardiac tissue (β1 subtype) are coupled to which intracellular signaling pathway that mediates the sympathetic increase in heart rate and AV nodal conduction velocity?
ANSWER: C
Rationale:
β1-adrenergic receptors couple to Gs proteins, which activate adenylyl cyclase and increase intracellular cyclic AMP. Elevated cyclic AMP activates protein kinase A (PKA), which phosphorylates multiple cardiac ion channels including HCN4 (increasing If, the pacemaker current), Cav1.2 (increasing ICaL), and phospholamban (increasing SR Ca2+ loading). This cascade produces the familiar sympathetic response: increased heart rate, AV nodal conduction velocity, and contractility. Beta-blockers competitively antagonize catecholamine binding at β1 receptors, reversing this entire cascade. Option E also describes Gi/IKACh coupling — the mechanism of vagal slowing, not adrenergic activation.
2. Beta-blockers suppress abnormal automaticity in subsidiary pacemakers and reduce SA nodal firing rate primarily by reversing catecholamine-induced changes to which ion channel?
ANSWER: A
Rationale:
PKA phosphorylation of HCN4 channels increases If amplitude and shifts the activation curve to more positive voltages, steepening the slope of spontaneous phase 4 depolarization in SA nodal and Purkinje cells. Beta-blockers reverse this shift by blocking the upstream adrenergic signal, reducing the intrinsic firing rate of the SA node and suppressing enhanced automaticity in subsidiary pacemakers. This is the primary mechanism underlying beta-blocker efficacy in inappropriate sinus tachycardia and exercise-induced ventricular arrhythmias. IKr, INa, ICaL, and IK1 are not the primary targets of adrenergic automaticity modulation.
3. On a surface ECG, the AV nodal slowing produced by beta-blockers is most directly reflected by which change?
ANSWER: E
Rationale:
Beta-blockers attenuate sympathetic stimulation of AV nodal conduction by reducing ICaL and If in nodal cells, prolonging AV nodal effective refractory period and slowing conduction velocity through the AV node. On the surface ECG, slower AV nodal conduction manifests as PR interval prolongation. QRS duration reflects His-Purkinje and ventricular conduction, which beta-blockers do not substantially affect at therapeutic doses. QT interval prolongation is not a feature of beta-blocker therapy. ST depression and T-wave changes reflect repolarization or ischemic processes unrelated to AV nodal slowing.
4. Esmolol's ultra-short duration of action (half-life approximately 9 minutes) results from which elimination mechanism?
ANSWER: B
Rationale:
Esmolol contains an ester linkage that is rapidly cleaved by esterases present in red blood cells, producing an inactive acid metabolite. This mechanism is entirely independent of hepatic or renal function, making esmolol safe in patients with liver or kidney impairment and ideally suited for settings requiring precise, rapidly reversible β1-blockade — perioperative tachyarrhythmias, thyroid storm, aortic dissection, and ICU rate control. Effects dissipate within 20–30 minutes of discontinuation. CYP3A4 hepatic metabolism, renal tubular secretion, adipose redistribution, and spontaneous hydrolysis are all incorrect elimination mechanisms for esmolol.
5. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a channelopathy caused by gain-of-function mutations in the cardiac ryanodine receptor (RyR2), producing pathologic sarcoplasmic reticulum Ca2+ leak during adrenergic stimulation and triggering bidirectional ventricular tachycardia with exercise or emotional stress. Which beta-blocker is preferred in CPVT and why?
ANSWER: E
Rationale:
CPVT arrhythmias are driven by adrenergic stimulation of both β1 and β2 receptors, both of which phosphorylate RyR2 and increase SR Ca2+ leak. Non-selective blockade of both receptor subtypes provides more complete suppression of catecholamine-triggered delayed afterdepolarizations (DADs — spontaneous depolarizations arising during phase 4 that can reach threshold and trigger arrhythmia) than β1-selective agents. Nadolol's renal clearance without hepatic metabolism and 14–24-hour half-life ensure consistent plasma levels, minimizing the troughs during which breakthrough adrenergic arrhythmias can occur. β1-selective agents such as metoprolol leave β2-mediated RyR2 activation intact, providing incomplete protection.
6. Which beta-blocker is correctly classified as β1-selective and undergoes primary hepatic metabolism via cytochrome P450 2D6 (CYP2D6, a hepatic enzyme responsible for the oxidative metabolism of approximately 25% of commonly prescribed cardiovascular and psychiatric drugs)?
ANSWER: C
Rationale:
Metoprolol is β1-selective and undergoes extensive hepatic metabolism primarily via CYP2D6. Patients who are CYP2D6 poor metabolizers achieve 3–5-fold higher plasma metoprolol concentrations at standard doses, substantially increasing the risk of bradycardia, hypotension, and AV block. Nadolol is non-selective and renally eliminated unchanged. Propranolol is non-selective and hepatically metabolized via CYP2D6 and CYP1A2. Atenolol is β1-selective but renally eliminated without significant hepatic metabolism. Esmolol is β1-selective but eliminated by red blood cell esterases, not CYP enzymes.
7. Propranolol is the preferred beta-blocker in thyrotoxicosis-related tachyarrhythmias for two pharmacologically distinct reasons. Which statement correctly identifies both?
ANSWER: A
Rationale:
Propranolol is preferred in thyrotoxicosis for two reasons. First, its non-selective β1+β2 blockade rapidly controls the tachycardia, hypertension, tremor, and agitation of thyroid storm. Second, propranolol uniquely blocks peripheral conversion of T4 to the more biologically active T3 by inhibiting the deiodinase enzyme responsible for this conversion — an effect mediated through β2 receptor blockade in peripheral tissues. This reduces the acute hormonal burden independently of sympathetic blockade. No other commonly used beta-blocker provides this T4→T3 conversion benefit. Propranolol is non-selective, not β1-selective, making option B incorrect. Membrane-stabilizing activity is pharmacologically demonstrable but not clinically relevant at standard doses.
8. Which beta-blocker possesses combined non-selective β-adrenergic blockade (β1 and β2) plus α1-adrenergic receptor blockade, and has demonstrated mortality benefit in heart failure with reduced ejection fraction (HFrEF) in randomized controlled trials?
ANSWER: E
Rationale:
Carvedilol is unique among beta-blockers in possessing combined non-selective β1+β2 blockade plus α1-adrenergic blockade. The α1-blocking property produces peripheral vasodilation, reducing afterload — a beneficial ancillary effect in HFrEF. Carvedilol demonstrated mortality benefit in the COPERNICUS trial (35% reduction in all-cause mortality in severe HFrEF, ejection fraction below 25%) and in CAPRICORN (post-MI with LV dysfunction). It is one of only three beta-blockers with proven mortality benefit in HFrEF (alongside metoprolol succinate and bisoprolol). Nadolol is non-selective without α-blockade. Atenolol and metoprolol tartrate are β1-selective without α-blockade and lack proven HFrEF mortality data.
9. Beta-blockers are uniquely effective in arrhythmias driven by delayed afterdepolarizations (DADs — spontaneous membrane depolarizations arising during phase 4 of the action potential that can reach threshold and trigger arrhythmia). Which cellular mechanism do beta-blockers interrupt to suppress DAD-mediated triggered activity?
ANSWER: B
Rationale:
Catecholamine excess drives intracellular Ca2+ overload through three PKA-mediated steps: phosphorylation of L-type Ca2+ channels (increasing Ca2+ entry), phospholamban (increasing SR Ca2+ loading), and RyR2 (increasing SR Ca2+ leak). The resulting excess cytosolic Ca2+ activates the sodium-calcium exchanger (NCX), which extrudes Ca2+ while moving Na+ inward — generating a net inward depolarizing current (INCX) that produces DADs. Beta-blockers interrupt this cascade at the upstream adrenergic step, preventing PKA activation and the downstream Ca2+ overload. This mechanism explains their efficacy in CPVT, exercise-induced VT, and arrhythmias complicating catecholamine excess states such as pheochromocytoma and myocarditis.
10. Beta-blockers are highly effective in long QT syndrome type 1 (LQT1) but have limited efficacy in long QT syndrome type 3 (LQT3). Which statement correctly explains this difference in terms of the underlying ion channel defects?
ANSWER: D
Rationale:
In LQT1, loss-of-function mutations in KCNQ1 reduce IKs, the primary repolarization reserve activated during sympathetic stimulation to shorten the action potential duration at faster rates. In LQT1, this reserve is absent, so adrenergic activation paradoxically worsens QT prolongation and precipitates torsades de pointes — characteristically triggered by exercise or sudden exertion. Beta-blockers prevent this by blocking the sympathetic signal that would otherwise worsen QT prolongation. In LQT3, the defect is SCN5A gain-of-function producing persistent late INa (INaL), which prolongs the action potential independent of adrenergic tone. Beta-blockers do not meaningfully reduce INaL; mexiletine, which blocks INaL directly, is the rational pharmacologic adjunct in LQT3.
11. In catecholaminergic polymorphic ventricular tachycardia (CPVT), the most common genetic defect involves gain-of-function mutations in which protein, and what is the direct electrophysiological consequence during adrenergic stimulation?
ANSWER: C
Rationale:
The most common form of CPVT (type 1, autosomal dominant) is caused by gain-of-function mutations in RyR2, the sarcoplasmic reticulum Ca2+ release channel. During adrenergic stimulation, PKA phosphorylation of the mutant RyR2 channel causes pathologic SR Ca2+ leak. The resulting cytosolic Ca2+ overload activates the sodium-calcium exchanger (NCX), generating a net inward depolarizing current that produces DADs (delayed afterdepolarizations — spontaneous depolarizations arising during phase 4). When DADs reach threshold, they trigger arrhythmias characteristically manifesting as bidirectional or polymorphic VT during exercise or emotional stress. The arrhythmia terminates at rest when adrenergic tone falls. This is why beta-blockade — particularly with non-selective agents — is the cornerstone of CPVT therapy.
12. Esmolol is administered intravenously for acute rate control in perioperative tachyarrhythmias and thyroid storm. Which dosing sequence correctly describes the standard esmolol infusion protocol?
ANSWER: A
Rationale:
Standard esmolol dosing consists of a loading dose of 500 mcg/kg IV administered over 1 minute to achieve rapid β-blockade, followed by a maintenance infusion at 50–300 mcg/kg/min titrated to heart rate response. The loading dose exploits esmolol's short half-life to achieve rapid steady-state. Because esmolol is eliminated by red blood cell esterases with a half-life of approximately 9 minutes, its hemodynamic effects dissipate within 20–30 minutes of discontinuation — making it readily reversible if hypotension or excessive bradycardia develops. Option E approximates IV procainamide or amiodarone dosing patterns.
13. A patient prescribed metoprolol tartrate 50 mg twice daily for rate control in atrial fibrillation develops symptomatic bradycardia (resting heart rate 38 bpm) and hypotension at a dose that is well tolerated by most patients. Genetic testing reveals she is a CYP2D6 poor metabolizer. What is the pharmacokinetic explanation for her exaggerated response?
ANSWER: E
Rationale:
Metoprolol is a CYP2D6 substrate. In extensive metabolizers (the majority of patients), metoprolol undergoes efficient hepatic oxidative metabolism with a half-life of 3–7 hours. In CYP2D6 poor metabolizers (approximately 7–10% of Caucasian populations), this metabolic pathway is severely impaired, resulting in 3–5-fold higher plasma metoprolol concentrations at identical doses. The clinical consequence is exaggerated β1-blockade: symptomatic bradycardia, hypotension, and AV block at doses routinely tolerated by the general population. This interaction is clinically important because many commonly co-prescribed drugs (fluoxetine, paroxetine, quinidine, bupropion) are CYP2D6 inhibitors that can convert an extensive metabolizer into a functional poor metabolizer phenotype.
14. Beta-blockers paradoxically improve long-term outcomes in heart failure with reduced ejection fraction (HFrEF) despite their acute negative inotropic properties. Which statement correctly describes the critical clinical rule governing beta-blocker initiation in HFrEF?
ANSWER: B
Rationale:
The critical clinical rule for beta-blocker initiation in HFrEF is that patients must be clinically compensated (euvolemic — not volume-overloaded or in pulmonary edema) before starting therapy. Initiating beta-blockers in decompensated HFrEF causes acute hemodynamic deterioration by reducing cardiac output in a heart already dependent on adrenergic support. Once the patient is euvolemic and stable, therapy begins at the lowest available dose (e.g., carvedilol 3.125 mg twice daily, metoprolol succinate 12.5–25 mg once daily) and is uptitrated slowly over weeks to months to the maximally tolerated dose. Patients already on beta-blockers who decompensate should have the dose halved rather than abruptly discontinued, to avoid the withdrawal hazard of receptor upregulation.
15. The MERIT-HF trial (1999) provided the primary evidence base for metoprolol succinate as a guideline-preferred agent in HFrEF. Which outcome did this trial demonstrate?
ANSWER: D
Rationale:
The MERIT-HF trial randomized 3,991 patients with stable HFrEF (ejection fraction 40% or less, NYHA Class II through IV) to metoprolol succinate CR/XL or placebo. The trial was stopped early due to a significant reduction in all-cause mortality in the metoprolol arm — relative risk reduction 34%, absolute risk reduction 3.8% per year. Sudden cardiac death was reduced by 41%. These results, combined with COPERNICUS (carvedilol) and CIBIS-II (bisoprolol), established that only these three agents — carvedilol, metoprolol succinate, and bisoprolol — have proven mortality benefit in HFrEF. Short-acting metoprolol tartrate, atenolol, and propranolol do not carry this evidence and should not be substituted in HFrEF.
16. A patient with coronary artery disease and a history of post-MI LV dysfunction has his beta-blocker abruptly discontinued by a covering physician on hospital day 2 for mild bradycardia. On day 3 he develops rebound tachycardia, angina, and is found to be in ventricular fibrillation. What is the pharmacologic mechanism underlying beta-blocker withdrawal syndrome?
ANSWER: C
Rationale:
Long-term beta-blocker therapy causes compensatory upregulation of β-adrenergic receptor density — a homeostatic response to chronic receptor blockade. When beta-blockers are abruptly discontinued, this supersensitive and upregulated receptor population is suddenly exposed to endogenous catecholamines without the buffering effect of the drug. The result is exaggerated adrenergic responses: rebound tachycardia, hypertension, angina from increased myocardial oxygen demand, and — in patients with coronary artery disease, post-MI LV dysfunction, CPVT, or LQTS — potentially fatal ventricular fibrillation. The risk is highest within the first 24–48 hours after abrupt discontinuation. The safe approach is tapering over 1–2 weeks whenever discontinuation is necessary.
17. A 62-year-old man with persistent atrial fibrillation (AF) is rate-controlled on digoxin but complains that his heart rate rises to 140–150 bpm during moderate exertion despite adequate resting rate control. What is the pharmacologic explanation for digoxin's inadequate rate control during exercise, and what class of agents is preferred for this indication?
ANSWER: A
Rationale:
Digoxin achieves AV nodal slowing primarily through vagotonic mechanisms — increasing parasympathetic tone via vagal sensitization. During exercise, the surge in sympathetic activity overwhelms this vagotonic effect, and the ventricular rate climbs despite adequate resting digoxin levels. Beta-blockers, by contrast, directly antagonize the adrenergic drive that accelerates AV nodal conduction during exercise, making them far superior for rate control in active patients. The 2023 ACC/AHA/ACCP/HRS AF guideline recommends beta-blockers (or non-DHP calcium channel blockers in patients without HFrEF) as preferred rate control agents, with digoxin reserved for patients who cannot tolerate or have contraindications to these agents, or as add-on therapy.
18. A 31-year-old man presents to the emergency department with chest pain, hypertension (BP 178/102 mmHg), and sinus tachycardia at 128 bpm following cocaine use. A colleague suggests IV metoprolol for rate and blood pressure control. Why is this approach contraindicated?
ANSWER: E
Rationale:
Cocaine blocks neuronal norepinephrine reuptake (and dopamine reuptake), producing intense α- and β-adrenergic stimulation simultaneously. In the normal physiologic state, β2-mediated vasodilation partially counterbalances α1-mediated vasoconstriction. Beta-blockers — even β1-selective agents — reduce the β2-vasodilatory component while leaving α1-mediated coronary and peripheral vasoconstriction unopposed. The result is paradoxical worsening of hypertension and coronary vasospasm — the primary cause of cocaine-related myocardial infarction. This contraindication applies to all beta-blockers, selective and non-selective. Management of cocaine-induced tachycardia and hypertension relies on benzodiazepines (reducing central sympathetic outflow), phentolamine (α-blockade) if needed, and supportive care.
19. A 67-year-old man with moderate COPD (chronic obstructive pulmonary disease; FEV1/FVC ratio 0.58) and new-onset AF at 128 bpm requires pharmacologic rate control. He is hemodynamically stable. Which beta-blocker approach is most appropriate?
ANSWER: B
Rationale:
COPD is not an absolute contraindication to cardioselective beta-blockers. β2-blockade is the mechanism responsible for bronchospasm; β1-selective agents (metoprolol, atenolol, bisoprolol) have substantially less β2 activity at therapeutic doses and are generally tolerated in COPD, particularly at low doses with close monitoring. Non-selective agents (propranolol, nadolol, carvedilol) block β2 receptors and exacerbate bronchospasm — they should be avoided in reactive airway disease. If bronchospasm develops despite β1-selectivity, switching to a non-DHP calcium channel blocker (diltiazem or verapamil) is appropriate. The bronchospasm risk of beta-blockers is related to receptor selectivity, not route of elimination.
20. Which combination of trials provides the primary evidence base for beta-blocker use in post-myocardial infarction (post-MI) arrhythmia prophylaxis and mortality reduction, and what magnitude of sudden cardiac death reduction did they collectively demonstrate?
ANSWER: D
Rationale:
The Beta-Blocker Heart Attack Trial (BHAT, 1982) randomized 3,837 post-MI patients to propranolol or placebo and demonstrated approximately 26% relative risk reduction in total mortality and 28% reduction in sudden cardiac death, establishing non-selective beta-blockade as standard post-MI therapy. CAPRICORN (2001) randomized 1,959 post-MI patients with LV dysfunction (ejection fraction 40% or less) to carvedilol or placebo, demonstrating a 23% reduction in all-cause mortality (hazard ratio 0.77). The mechanistic basis for both trials is beta-blocker suppression of catecholamine-driven triggered activity and reduction of the ischemic arrhythmia substrate. CAST and SWORD demonstrated excess mortality with Class Ic and Class III agents post-MI — the opposite finding, establishing that not all antiarrhythmics are beneficial post-MI.
21. The POISE trial (2008) randomized 8,351 patients undergoing non-cardiac surgery to extended-release metoprolol succinate or placebo. Metoprolol reduced the incidence of AF and myocardial infarction but significantly increased 30-day mortality. What is the correct interpretation of this finding for current perioperative beta-blocker practice?
ANSWER: C
Rationale:
The POISE trial demonstrated that high-dose metoprolol succinate (100 mg starting 2–4 hours before surgery, then 200 mg postoperatively) in beta-blocker-naive patients significantly increased 30-day mortality (3.1% vs. 2.3%), with excess events attributable to hypotension-related deaths and stroke. The lesson is not that perioperative beta-blockade is harmful per se, but that high-dose initiation immediately before non-cardiac surgery in patients not previously taking these agents causes excess harm. Current ACC/AHA perioperative guidelines recommend: continuing beta-blockers in patients already taking them; initiating in high-risk patients at low doses at least one week before elective surgery with careful titration; and never initiating high-dose beta-blockers on the day of surgery in beta-blocker-naive patients. IV esmolol remains the preferred agent for managing acute intraoperative tachyarrhythmias.
22. A 24-year-old woman with long QT syndrome type 3 (LQT3) — caused by a gain-of-function SCN5A mutation producing persistent late INa (INaL, an abnormal persistent inward sodium current during phase 2–3 of the action potential) — is currently on nadolol. Her cardiologist notes that beta-blockers have limited efficacy in LQT3 compared to LQT1 and considers adding a second agent. Which drug would be the most rational pharmacologic adjunct for LQT3 specifically, and why?
ANSWER: A
Rationale:
In LQT3, the underlying defect is a gain-of-function SCN5A mutation producing persistent late INa (INaL) — an abnormal inward sodium current that persists into phase 2–3 of the action potential, prolonging action potential duration and QT interval independent of adrenergic tone. Beta-blockers, which work by blocking adrenergic activation of channel phosphorylation, do not meaningfully reduce INaL and therefore have limited antiarrhythmic efficacy in LQT3. Mexiletine is a Class Ib sodium channel blocker (lidocaine analog) that preferentially blocks INaL at low concentrations while minimally affecting peak INa, directly targeting the pathophysiologic current. Multiple case series and small trials demonstrate QT shortening and arrhythmia reduction with mexiletine in LQT3. Flecainide (Class Ic) blocks peak INa powerfully but is contraindicated in structural heart disease. Amiodarone prolongs the QT interval further and would be counterproductive.
BEFORE YOU MOVE ON
You have just worked through the foundational pharmacology of Class II antiarrhythmic agents — the beta-blockers. If you answered the mechanism questions in S1 correctly, you can now trace the path from β1-receptor activation through Gs/cAMP/PKA to the specific ion channels that drive arrhythmia, and explain precisely where in that cascade beta-blockers intervene. If the S2 questions challenged you, particularly the channelopathy questions (CPVT, LQT1, LQT3), go back and read those rationales carefully — the distinction between DAD-driven arrhythmias (where adrenergic blockade is mechanistically curative) and non-adrenergic arrhythmias (where it is not) is a theme that will recur across Modules 4 through 9. The S3 questions asked you to apply this pharmacology to recognizable clinical scenarios: the patient with COPD needing rate control, the cocaine presentation where a reflex reach for beta-blockade is dangerous, the perioperative patient whose established therapy should be continued rather than abruptly stopped. Tier 1 questions for this module will build directly on these scenarios, asking you to manage more complex patients — competing comorbidities, dose selection, and the decision between agents — with the same pharmacologic principles you have just demonstrated. You are ready for that step.